Substance / Medication

Thiabendazole

Overview

Active Ingredient
thiabendazole
RxNorm CUI
10450

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

6 trials linked to this intervention

6
Total Trials
2
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Epidemiology of taeniosis, cysticercosis and trichinellosis in Iran: A systematic review.
Moazeni Mohammad, Khamesipour Faham, Anyona Douglas N et al. · Zoonoses Public Health · 2019
PMID: 30575317Meta-Analysis
Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.
Henriquez-Camacho Cesar, Gotuzzo Eduardo, Echevarria Juan et al. · Cochrane Database Syst Rev · 2016
PMID: 26778150Meta-AnalysisFull text (PMC)
Reviews on trichinellosis (IV): hepatic involvement.
Neghina Raul, Neghina Adriana Maria · Foodborne Pathog Dis · 2011
PMID: 21524198Meta-Analysis
Prevalence of meat-transmitted Taenia and Trichinella parasites in the Far East countries.
Liu Yi, Dong Zijian, Pang Jianda et al. · Parasitol Res · 2021
PMID: 33768333Review
Reprint of: A review on Trichinella infection in South America.
Ribicich M Mabel, Fariña Fernando A, Aronowicz Tatiana et al. · Vet Parasitol · 2021
PMID: 34384644Review
Randomized clinical trial on ivermectin versus thiabendazole for the treatment of strongyloidiasis.
Bisoffi Zeno, Buonfrate Dora, Angheben Andrea et al. · PLoS Negl Trop Dis · 2011
PMID: 21814588TrialFull text (PMC)
Treatment of pediculosis capitis with thiabendazole: a pilot study.
Namazi Mohammad Reza · Int J Dermatol · 2003
PMID: 14636196Trial
Thiabendazole for the treatment of strongyloidiasis in patients with hematologic malignancies.
Schaffel R, Nucci M, Portugal R et al. · Clin Infect Dis · 2000
PMID: 11017840Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tiabendazole (substance)
SNOMED CT
416624006
UMLS CUI
C0039832
RxNorm CUI
10450

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
6
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.